( oteworthy by themeeting organizers and...)Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia,Long-Term Safety Data at AAN Annual Meeting,Health

Zenvia investigator Daniel Wynn, MD, ABSM, Co-Director of the Clinical Research Consultants in Neurology MS Center in Northbrook, IL, presented poster P01.015 "Long-Term Safety of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Involuntary Emotional Expression Disorder (IEED)." Data were presented from patients with IEED, secondary to various neurologic diseases or injuries, treated with Zenvia for 52 weeks or longer. Results indicated that adverse events were generally mild to moderate in nature with decreasing frequency after the first week of therapy; no differences in adverse event profile based on age, sex, race or underlying neurologic disease; no treatment-related serious adverse events; and no clinically meaningful effects on cardiac repolarization or any electrocardiogram variables.

In this open-label, multi-center study, 506 IEED patients with multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's dementia, Parkinson's disease, or injuries such as stroke and traumatic brain injury, were enrolled to evaluate long-term safety and tolerability with 321 patients completing more than six months of treatment. Eighty-six percent of the 234 patients who completed one year of therapy chose to continue in the optional extension phase of the study. The median compliance rate with Zenvia therapy was 97.1%.

Linda Werling, Ph.D., Director, Institute for Biomedical Sciences, George Washington University Medical Center, presented poster P01.016 "Competitive Binding of Dextromethorphan to Selective Brain Receptor Sites." This study evaluated radioligand competitive binding for memantine, amitriptyline, fluoxetine, dextrorphan and dextromethorphan, the therapeutically active ingredient in Zenvia, to determine the binding affinities for
'"/>